Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-401-4060
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.50 million
Profitability
Miscellaneous
Employees72
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions
What is Ra Pharmaceuticals' stock symbol?
Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."
How were Ra Pharmaceuticals' earnings last quarter?
Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.49) by $0.02. The company earned $2.50 million during the quarter, compared to analysts' expectations of $2.50 million. View Ra Pharmaceuticals' Earnings History.
When is Ra Pharmaceuticals' next earnings date?
What price target have analysts set for RARX?
7 brokerages have issued twelve-month target prices for Ra Pharmaceuticals' stock. Their predictions range from $25.00 to $55.00. On average, they anticipate Ra Pharmaceuticals' share price to reach $40.7143 in the next year. This suggests a possible upside of 85.4% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.
What is the consensus analysts' recommendation for Ra Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals.
Has Ra Pharmaceuticals been receiving favorable news coverage?
News headlines about RARX stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Ra Pharmaceuticals' key competitors?
Some companies that are related to Ra Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Insmed (INSM), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Portola Pharmaceuticals (PTLA) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Ra Pharmaceuticals own?
Who are Ra Pharmaceuticals' key executives?
Ra Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
- Mr. David C. Lubner, Exec. VP & CFO (Age 55)
- Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
- Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
- Dr. Simon Read, Chief Scientific Officer (Age 48)
When did Ra Pharmaceuticals IPO?
(RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.
Who are Ra Pharmaceuticals' major shareholders?
Ra Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Manhattan Co. (3.36%) and Rhenman & Partners Asset Management AB (0.36%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.
Which major investors are selling Ra Pharmaceuticals stock?
Which major investors are buying Ra Pharmaceuticals stock?
RARX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.
How do I buy shares of Ra Pharmaceuticals?
Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ra Pharmaceuticals' stock price today?
One share of RARX stock can currently be purchased for approximately $21.96.
How big of a company is Ra Pharmaceuticals?
Ra Pharmaceuticals has a market capitalization of $926.45 million and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.
What is Ra Pharmaceuticals' official website?
How can I contact Ra Pharmaceuticals?
Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]
MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
